Entete 3

Monthly Archives: April 2019

A multidisciplinary self-management intervention among patients with multimorbidity: Impact of socioeconomic factors

By Martin Fortin
The objective of this study was to analyze the effect of a multidisciplinary self-management intervention among patients with multimorbidity and the impact of socioeconomic factors on the results.
Participants of this study were multimorbid patients from of a pragmatic randomized trial evaluating an intervention that included patients (18 to 75 yrs.) from eight primary care practices in Quebec, Canada. The intervention included self-management support and patient-centered motivational approaches.
Self-management was evaluated using the Health Education Impact Questionnaire (heiQ) which measures eight different domains.
The effect of the intervention on the likelihood of an improvement in self-management was significant in six heiQ domains in the univariate analysis: Health-directed behavior, Emotional well-being, Self-monitoring and insight, Constructive attitudes and approaches, Skill and technique acquisition, and Health services navigation. After controlling for age and gender the results remained essentially the same.
After additional adjustments for family income, education and self-perceived financial status, the likelihood of an improvement was no longer significant in the domains Emotional well-being and Self-monitoring and insight.
It was concluded that the intervention produced significant improvements in multimorbid patients for most domains of self-management but socioeconomic factors had a minor impact on the results.
.
The complete article can be accessed at the following link:

Improving patient-centred care for multimorbidity

By Chris Salisbury, University of Bristol, on behalf of the 3D trial team.
.
Full report of the 3D study helps us interpret the findings
.
The 3D approach was designed to improve care for patients with multimorbidity. Based on a patient-centred care approach, it promotes continuity of care, offers a comprehensive holistic review which focuses on problems that most matter to the patient, and seeks to reduce inappropriate polypharmacy. The reviews involve a six-monthly multi-disciplinary review from a nurse, pharmacist and GP, leading to a health plan with specific goals agreed between the patient and GP. The 3D model incorporates most of the strategies recommended in international guidelines on multimorbidity.
We conducted a large cluster randomised controlled trial comparing the 3D approach and usual care, and the main trial results were published in the Lancet in July 2018 [1]. We found that the 3D intervention was effective at improving patient centred care, but did not result in improvements in patient’s quality of life, health outcomes or polypharmacy.
How should we make sense of these counter-intuitive results? Are the current international guidelines misconceived?  Perhaps the 3D approach was the wrong intervention, perhaps it was not effectively implemented or not provided for the long enough to make a difference. Or maybe we chose the wrong outcome measures. Interestingly, the conclusion that the 3D approaches improves patient-centred care but not quality of life is consisent with most previous trials of interventions for multimorbidity.
The Lancet paper has generally been interpreted as reporting a negative trial. The full report of the 3D study has now been published [2], and provides a more rounded perspective on the findings. It includes a process evaluation based on interviews with patients and staff, along with direct observation in case-study practices to help us understand how the 3D approach was implemented and how it might be improved. The full report also includes an economic evaluation of cost-effectiveness.
Through the process evaluation we found that practices were strongly supportive of the principles underlying the 3D approach, but they found implementing it logistically difficult. Many patients in the trial did not receive the full ‘dose’ of the intervention. Only half of the patients received two 3D reviews over 15 months as intended, while three-quarters received at least one review. This incomplete implementation was related to the pressures that general practices in the UK currently face, which made introducing any kind of change very difficult. Trying to do so within the context of a trial made it even more difficult. Introducing a new way of working for a limited period for a sub-set of patients, within practices which had well-established systems for offering single-disease care designed to meet the requirements of the Quality and Outcomes Framework, meant that not everything worked as planned. For example, some practices offered 3D reviews as well as, rather than instead of, single-disease reviews. However, practices did identify ways in which the 3D model might be improved, for example by more selectively targeting patients with the most complex problems, more training for staff and tailoring the frequency of reviews according to patients’ needs.
The economic evaluation showed that the 3D intervention was associated with small improvements in quality-adjusted life years (QALYs) along with small increases in NHS costs. The cost per QALY was £18,499, just below the threshold of £20,000 commonly used to justify new interventions in the NHS. Therefore the economic case for introducing 3D is arguable, and could be justified given that it provided care in a way that patient’s preferred and which they felt met their needs.
In summary, the report describes the advantages and limitations of the 3D approach, and ways in which it might be improved. There doesn’t appear to be a simple magic bullet to improve care for multimorbidity and no model of care has yet been convincingly shown to be effective in randomised trials. Paradoxically, one key finding from the report is that the 3D approach would probably need to become normal practice and offered over several years before the benefits became apparent, but testing this hypothesis in an affordable randomised trial would almost certainly be impossible.
.
This project was funded by the National Institute for Health Research Health Services and Delivery Research Programme (project number 12/130/15). The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the HS&DR Programme, NIHR, NHS or the Department of Health.
.